ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024
Determination of a cut-off COmprehensive Score for financial Toxicity (COST) for identifying cost-related treatment nonadherence and impaired health-related quality of life among Chinese patients with cancer.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Reply to: Letter to the Editor Concerning "Financial Toxicity Among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study".Annals of surgical oncology · 2026Article
- Factors influencing nurses' knowledge on peripherally inserted central catheter care in Guizhou, China: A web-based cross-sectional study.Scientific reports · 2026Article
- [Current status and prospects of family financial toxicity in childhood malignancies].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Review
- Mediating Role of Family Resilience and Avoidance Between Financial Toxicity and Quality of Life in Cancer Patients: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Barriers to continuity of outpatient infusion-port maintenance among patients with cancer: a single-center cross-sectional study in China.Frontiers in public health · 2026Observational
- Latent profile analysis of self-management and its association with quality of life differences in patients with cancer treated with immune checkpoint inhibitors.Asia-Pacific journal of oncology nursing · 2025Article
- Disparities in cancer-related financial toxicity across economically diverse provinces in China: A multi-center cross-sectional study.Asia-Pacific journal of oncology nursing · 2025Article
- Development of an indirect ELISA based on a new specific lipoprotein LP53 for the detection of antibodies against Mycoplasma synoviae.BMC veterinary research · 2025Article
- Financial toxicity and its risk factors among patients with cancer in China: A nationwide multisite study.Asia-Pacific journal of oncology nursing · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to determine a cut-off for the simplified Chinese version of the COmprehensive Score for financial Toxicity (COST) that could identify cost-related treatment nonadherence among Chinese patients with cancer. The study also sought to validate this cut-off score by using it to assess impaired health-related quality of life (HRQoL) in the same population.
methodsA secondary analysis was conducted using data from a cross-sectional survey of 1208 Chinese patients with cancer who were recruited from 12 hospitals in six cities across three provinces of the Chinese mainland. Sociodemographic information and data on financial toxicity (FT), cost-related treatment nonadherence, and HRQoL were used in the analysis. Receiver operating characteristic (ROC) analysis was used to determine the optimal cut-off for the simplified Chinese version of the COST.
resultsThe ROC analysis identified a COST cut-off of 18.5 for identifying cost-related treatment nonadherence, yielding a sensitivity of 76.5% and specificity of 71.4%. In the validation study, this cut-off score yielded a sensitivity of 64.2% and a specificity of 67.1% for identifying impaired HRQoL.
conclusionEarly and dynamic assessment of cancer-related FT in routine clinical practice may play a crucial role in the early identification and management of FT. Accordingly, a COST cut-off of 18.5 was identified to indicate cost-related treatment nonadherence and impaired HRQoL in a population of patients with cancer from the Chinese mainland. This finding may facilitate the implementation of universal FT screening among patients with cancer in specific settings such as the Chinese mainland.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.